Business · 16/05/2011Updated: 10/17/2026 · 1 min read
FDA Reopens Comment Period for PRISTIQ Patent Extension
Summary
The FDA is reopening the comment period for PRISTIQ, a medication, to allow interested parties to submit comments or petitions regarding the regulatory review period for patent extension, following the correction of omitted notices in the Federal Registers.
Original source language: Federal Register — Health and Human ServicesOpen original release →